

## **NECTAR LIFESCIENCES LIMITED**

Regd.Office:Vill.Saidpura,Tehsil Derabassi,Distt.Mohali,(Punjab), Corporate Identification Number: L24232PB1995PLC016664
Tel. +91-17 62-30 8000, Fax +91-17 62-30 8135, Email: sunderlal@neclife.com, Website: www.neclife.com

Part I Statement of Unaudited Financial Results for the Quarter and Six Months ended 30.09.2015 (Rs in Lacs)

S.	PARTICULARS	Quarter ended	Quarter ended	Quarter ended	Half Year ended	Half Year ended	Year ended
No		30-09-15	30-06-15	30-09-14	30-09-15	30-09-14	31-03-15
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Income from Operations						
	(a) Gross Sales	42,156.76	43,152.19	42,113.15	85,308.95	82,326.69	174,638.61
	Less : Excise Duty	2,490.18	2,383.51	2,739.58	4,873.69	4,795.33	10,349.72
	Net Sales	39,666.59	40,768.68	39,373.57	80,435.27	77,531.36	164,288.89
	(b) Other Operating Income	0.17	1.52	15.14	1.68	29.19	75.30
	Total Income from Operations (net)	39,666.75	40,770.20	39,388.71	80,436.95	77,560.55	164,364.19
2.	Expenses						
	(a) Cost of Materials consumed	25,583.76	26,469.33	24,794.12	52,053.09	50,110.26	112,990.38
	(b) Purchase of Stock in Trade (c) Changes in inventories of finished goods, work-in-progress	1,038.60	854.58 290.36	725.92	1,893.18 130.13	2,150.09	3,960.61
	and stock-in-trade	(160.23)	290.50	1,043.70	150.15	902.14	(2,817.56)
	(d) Employee benefits expense	1,716.88	1,686.87	1,463.37	3,403.74	2,850.51	6,270.67
	(e) Depreciation and amortisation expense	2,194.06	2,178.71	1,887.72	4,372.77	3,810.98	7,656.43
	(f) Other expenses	4,128.26	4,413.68	4,129.75	8,541.94	7,742.05	17,269.38
	Total Expenses	34,501.33	35,893.53	34,044.58	70,394.85	67,566.03	145,329.91
3.	Profit from Operations before Other Income, finance						
	costs and exceptional Items (1-2)	5,165.42	4,876.67	5,344.13	10,042.10	9,994.52	19,034.28
4.	Other Income	127.02	126.71	266.31	253.73	496.54	1,999.88
5.	Profit before finance costs and exceptional Items (3+4)	5,292.44	5,003.39	5,610.44	10,295.83	10,491.06	21,034.16
6.	Finance costs	3,082.20	2,733.24	3,548.48	5,815.44	6,388.59	12,558.79
7. 8.	Profit after finance costs but before exceptional Items (5-6)	2,210.24	2,270.14	2,061.96	4,480.39	4,102.47	8,475.37
9.	Exceptional Items Profit from ordinary activities before tax (7+8)	2,210.24	2,270.14	2,061.96	4,480.39	4,102.47	8,475.37
10.	Tax Expense	477.80	528.80	420.17	1,006.60	835.64	1,848.98
11.	Net Profit from ordinary activities after tax (9-10)	1,732.45	1,741.34	1,641.79	3,473.79	3,266.83	6,626.39
12.	Extraordinary Item (net of tax expense)	-	-	-	-	-	-
13.	Net Profit for the period (11-12)	1,732.45	1,741.34	1,641.79	3,473.79	3,266.83	6,626.39
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61
15.	Reserves excluding Revaluation Reserves	-	-	-	-	-	93,552.29
16.i	Earnings per Share (EPS) (before extraordinary items)						
	a) Basic	0.77	0.78	0.73	1.55	1.46	2.95
	b) Diluted	0.77	0.78	0.73	1.55	1.46	2.95
16.ii	Earnings per Share (EPS) (after extraordinary items)						
	a) Basic	0.77	0.78	0.73	1.55	1.46	2.95
	b) Diluted	0.77	0.78	0.73	1.55	1.46	2.95
	,						
Α	Particulars of shareholding		Quarter and six ii		,3. <u>2013</u>		
1.	Public Shareholding						
1.	- Number of Shares	124,792,970	124,792,970	124,792,970	124,792,970	124,792,970	124,792,970
	- Percentage of Shareholding	55.65	55.65		55.65		55.65
<u> </u>		55.05	55.05	55.65	55.05	55.65	55.05
2.	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered	FF FFF 600	FF FFF 600	FF FFF 600	FF FFF 600	FF FFF 600	FF FFF 600
	- Number of Shares	55,555,600	55,555,600	55,555,600	55,555,600	55,555,600	55,555,600
	- Percentage of Shares ( as a % of the total shareholding of	55.85	55.85	55.85	55.85	55.85	55.85
	promoter and promoter group)						
	- Percentage of Shares ( as a % of the total share capital of	24.77	24.77	24.77	24.77	24.77	24.77
	the company)						
	b) Non-encumbered						
	- Number of Shares	43,912,400	43,912,400	43,912,400	43,912,400	43,912,400	43,912,400
	- Percentage of Shares ( as a % of the total shareholding of	44.15	44.15	44.15	44.15	44.15	44.15
	promoter and promoter group)						
	- Percentage of Shares ( as a % of the total share capital of	19.58	19.58	19.58	19.58	19.58	19.58
L	the company)						

В	Investor Complaints	3 Months ended 30.09.2015
	Pending at the beginning of Quarter	-
	Received During the Quarter	26
	Disposed Off During the Quarter	26
	Pending at the end of Quarter	-

Statement of Assets and Liabilities	(Rs in Lacs)	
PARTICULARS		As at
	30-09-15	31-03-15
	Unaudited	Audited
SHAREHOLDERS' FUND		
(I) Capital	2,242.61	2,242.61
(ii) Reserves and Surplus	97,026.03	93,552.29
NON CURRENT LIABILITIES		
(i) Long Term Liabilities	28,027.46	26,552.92
(ii) Deffered Tax Liability	11,726.07	11,019.28
(iii) Other Long Term Liabilities	1,763.73	1,518.72
(iv) Long Term Provisions	664.40	601.13
CURRENT LIABILITIES		
(i) Short Term Borrowings	59,510.14	59,529.78
(ii) Trade Payables	43,187.06	45,557.72
(iii) Other Current Liabilities	11,751.38	9,050.00
(iv) Short Term Provisions	1,790.82	1,422.15
Total	257,689.70	251,046.60
NON CURRENT ASSETS		
(i) Fixed Assets (Incl CWIP)	102,078.18	102,504.37
(ii) Non Current Investments	5.01	5.01
(iii) Long Term Loans & Advances	8,263.30	8,044.27
(iv) Other Non Current Assets	5,324.79	3,591.24
CURRENT ASSETS		
(i) Current Investments	43.51	43.51
(ii) Inventories	81,938.70	79,097.46
(iii) Trade Receivables	43,736.79	44,649.64
(iv) Cash & Bank Balances	2,626.31	3,338.20
(v) Short Term Loans & Advances	11,294.76	8,143.15
(vi) Other Current Assets	2,378.35	1,629.75
Total	257,689.70	251,046.60

## Notes:

Dated: 13.11.15

- 1 The above financial results were reviewed by Audit Committee on 12.11.15 and approved by the Board in its meeting held on even date i.e. 13.11.15 and further limited reviewed by the Statutory Auditors of the Company.
- 2 The company is exclusively in the pharmaceutical business segment.
- 3 The Shareholders in their Annual General Meeting held on 30.09.2015 have declared the final dividend of Re. 0.10/- per equity share (10% on the face value of Re. 1/- per equity share) for the financial year 2014-15. The Company has despatched Dividend Warrants to the shareholders at their registered addresses, and wherever applicable, the Dividend has been credited to the shareholders' accounts directly through National Electronic Credit Settlement (NECS/ECS/NEFT/ Direct Credit) facility of RBI.
- 4 Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- 5 The above financial results are on stand alone basis.

By Order of the Board of Directors of Nectar Lifesciences Limited sd/-

. \_

(Dinesh Dua)

Place: Chandigarh Chief Executive Officer & Director